Radiopharm Theranostics Ltd earns nearly six-fold price upside on recent developments, successful execution: Diamond Equity Research
Radiopharm Theranostics Ltd (ASX:RAD) (RAD) has earned a price valuation of $0.70 per share, an implied upside of nearly six times its current share price...